当前位置： SCI文献检索 > CLINICAL PHARMACOKINETICS期刊下所有文献 > Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.

Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.

Abstract：

:Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool used to characterize maturational changes in drug disposition to inform dosing across childhood; however, its use is limited in pediatric drug development. Access to pediatric pharmacokinetic data is a barrier to widespread application of this model, which impedes its development and optimization. To support the development of a pediatric PBPK model, we sought to leverage opportunistically-collected plasma concentrations of the commonly used antibiotic clindamycin. The pediatric PBPK model was optimized following development of an adult PBPK model that adequately described literature data. We evaluated the predictability of the pediatric population PBPK model across four age groups and found that 63-93% of the observed data were captured within the 90% prediction interval of the model. We then used the pediatric PBPK model to optimize intravenous clindamycin dosing for a future prospective validation trial. The optimal dosing proposed by this model was 9 mg/kg/dose in children ≤5 months of age, 12 mg/kg/dose in children >5 months-6 years of age, and 10 mg/kg/dose in children 6-18 years of age, all administered every 8 h. The simulated exposures achieved with the dosing regimen proposed were comparable with adult plasma and tissue exposures for the treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Our model demonstrated the feasibility of using opportunistic pediatric data to develop pediatric PBPK models, extending the reach of this powerful modeling tool and potentially transforming the pediatric drug development field.

journal_name

Clin Pharmacokinet

journal_title

Clinical pharmacokinetics

authors

Hornik CP,Wu H,Edginton AN,Watt K,Cohen-Wolkowiez M,Gonzalez D

doi

10.1007/s40262-017-0525-5

subject

Has Abstract

pub_date

2017-11-01 00:00:00

pages

1343-1353

issue

11

eissn

0312-5963

issn

1179-1926

pii

10.1007/s40262-017-0525-5

journal_volume

56

pub_type

杂志文章

相关文献

CLINICAL PHARMACOKINETICS文献大全
  • Pharmacokinetics and pharmacodynamics of pegfilgrastim.

    abstract：:Pegfilgrastim is a sustained-duration form of filgrastim, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), to which a 20  kDa polyethylene glycol molecule is covalently bound to the N-terminal methionine residue. Similar to filgrastim, pegfilgrastim increases the proliferation and d...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/11586040-000000000-00000

    authors： Yang BB,Kido A

    更新日期：2011-05-01 00:00:00

  • The clinical pharmacokinetics of escitalopram.

    abstract：:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and rea...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200746040-00002

    authors： Rao N

    更新日期：2007-01-01 00:00:00

  • Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations.

    abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-016-0420-5

    authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

    更新日期：2016-12-01 00:00:00

  • Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

    abstract：BACKGROUND AND OBJECTIVE:Inolimomab, a monoclonal antibody against interleukin (IL)-2Ralpha (CD25) has shown promising results in the treatment of corticosteroid-resistant acute graft-versus-host disease (GvHD). The objective of the present study was to characterise the pharmacokinetic and pharmacodynamic properties of...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200746050-00004

    authors： Dartois C,Freyer G,Michallet M,Hénin E,You B,Darlavoix I,Vermot-Desroches C,Tranchand B,Girard P

    更新日期：2007-01-01 00:00:00

  • Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

    abstract：:Clinical pharmacokinetics emerged as a clinical discipline in the late 1960s and early 1970s. Clinical pharmacokinetic monitoring (CPM) helped many pharmacists to enter the clinical arena, but the focus was more on the pharmacists and tools. With the widespread acceptance of pharmaceutical care and patient-focused pha...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199834040-00001

    authors： Ensom MH,Davis GA,Cropp CD,Ensom RJ

    更新日期：1998-04-01 00:00:00

  • Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

    abstract：:Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199324040-00007

    authors： Hasselström J,Säwe J

    更新日期：1993-04-01 00:00:00

  • Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

    abstract：BACKGROUND AND OBJECTIVE:Febuxostat is a xanthine oxidase inhibitor indicated for gout and hyperuricemia. This work investigates potential clinically relevant covariates for febuxostat pharmacokinetics with a special focus on Asian race and bodyweight. METHODS:Febuxostat plasma concentrations from 141 male subjects we...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00943-6

    authors： Rekić D,Johansson S,Leander J

    更新日期：2020-09-19 00:00:00

  • Clinical pharmacokinetics of sevoflurane.

    abstract：:Sevoflurane is a comparatively recent addition to the range of inhalational anaesthetics which has been recently released for clinical use. In comparison to older inhalational agents such as isoflurane or halothane, the most important property of sevoflurane is its low solubility in the blood. This results in a more r...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199936010-00002

    authors： Behne M,Wilke HJ,Harder S

    更新日期：1999-01-01 00:00:00

  • A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

    abstract：BACKGROUND AND OBJECTIVES:Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated clinical activity in a number of different cancer types. The objectives of this study were to characterize the pharmacokinetics of abemaciclib in cancer patients using population pharmacokinetic (popPK) modelin...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s40262-017-0559-8

    authors： Tate SC,Sykes AK,Kulanthaivel P,Chan EM,Turner PK,Cronier DM

    更新日期：2018-03-01 00:00:00

  • Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.

    abstract：:The various components required for individualising clinical drug dosage regimens are reviewed, including a study of 3 types of fitting procedures, 2 types of gentamicin pharmacokinetic model and the utility of D-optimal times for obtaining serum gentamicin concentrations. The combination of the current Bayesian fitti...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199121060-00006

    authors： Jelliffe RW,Iglesias T,Hurst AK,Foo KA,Rodriguez J

    更新日期：1991-12-01 00:00:00

  • Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease.

    abstract：OBJECTIVE:To obtain a pharmacokinetic profile of cyclosporin microemulsion formulation in patients with inflammatory bowel disease. PATIENTS AND PARTICIPANTS:58 consecutive patients (19 women and 39 men), aged 16 to 64 years (mean age 38 years), with a diagnosis of ulcerative colitis (29 patients) or Crohn's disease (...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200140060-00006

    authors： Latteri M,Angeloni G,Silveri NG,Manna R,Gasbarrini G,Navarra P

    更新日期：2001-01-01 00:00:00

  • Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.

    abstract：BACKGROUND AND OBJECTIVE:Losmapimod is an orally available, potent p38 mitogen-activated protein kinase inhibitor. It is in development as an anti-inflammatory drug in different therapeutic areas. Clinical studies have shown that losmapimod is well tolerated and safe in humans and several studies have shown its pharmac...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-012-0025-6

    authors： Yang S,Lukey P,Beerahee M,Hoke F

    更新日期：2013-03-01 00:00:00

  • Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin.

    abstract：:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198510060-00004

    authors： Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

    更新日期：1985-11-01 00:00:00

  • Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

    abstract：BACKGROUND AND OBJECTIVE:Taurolidine is known to have antimicrobial activity. Furthermore, at lower concentrations, it has been found to exert a selective antineoplastic effect in vitro and in vivo. The aim of this study was to investigate the pharmacokinetics of taurolidine in vivo following repeated intravenous infus...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200746060-00005

    authors： Stendel R,Scheurer L,Schlatterer K,Stalder U,Pfirrmann RW,Fiss I,Möhler H,Bigler L

    更新日期：2007-01-01 00:00:00

  • Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

    abstract：BACKGROUND AND OBJECTIVES:The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at least partly due to highly variable placebo effects, have indicated the necessity for a ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/11598460-000000000-00000

    authors： Pilla Reddy V,Kozielska M,Johnson M,Suleiman AA,Vermeulen A,Liu J,de Greef R,Groothuis GM,Danhof M,Proost JH

    更新日期：2012-04-01 00:00:00

  • Drug protein binding and the nephrotic syndrome.

    abstract：:A reduction in plasma albumin concentration, as seen in patients with the nephrotic syndrome, is usually associated with a decrease in plasma protein binding of highly bound drugs. Therefore, the fraction of the unbound drug increases, but the absolute free concentration remains essentially unchanged due to a compensa...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-197601010-00003

    authors： Gugler R,Azarnoff DL

    更新日期：1976-01-01 00:00:00

  • Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.

    abstract：:Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced platelet activation via P2Y(12) receptors plays a pivotal role in the pathophysiology of ACS. The current standard of treatmen...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/11630960-000000000-00000

    authors： Teng R

    更新日期：2012-05-01 00:00:00

  • Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

    abstract：:The pharmacokinetics and antihypertensive effects of felodipine, a new dihydropyridine calcium channel blocker, were studied in elderly hypertensive patients, 67 to 79 years of age and in young healthy subjects, 20 to 34 years of age following oral administration of 5 mg twice daily to steady-state. A single intraveno...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198814060-00004

    authors： Landahl S,Edgar B,Gabrielsson M,Larsson M,Lernfelt B,Lundborg P,Regårdh CG

    更新日期：1988-06-01 00:00:00

  • Clinical pharmacokinetics of the salicylates.

    abstract：:The use of salicylates in rheumatic diseases has been established for over 100 years. The more recent recognition of their modification of platelet and endothelial cell function has lead to their use in other areas of medicine. Aspirin (acetylsalicylic acid) is still the most commonly used salicylate. After oral admin...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198510020-00004

    authors： Needs CJ,Brooks PM

    更新日期：1985-03-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

    abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-017-0620-7

    authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

    更新日期：2018-07-01 00:00:00

  • Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

    abstract：:The pharmacokinetics of dothiepin were evaluated in 9 depressed patients following a single oral dose of 75 mg. Blood and plasma concentrations of dothiepin and 2 major metabolites, northiaden and dothiepin S-oxide, were measured by gas chromatography/mass fragmentography. The mean (+/-SD) peak plasma concentrations o...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198308020-00004

    authors： Maguire KP,Norman TR,McIntyre I,Burrows GD

    更新日期：1983-03-01 00:00:00

  • Plasma level monitoring of antipsychotic drugs. Clinical utility.

    abstract：:The steady-state plasma concentrations of antipsychotic drugs show large interpatient variations but remain relatively stable from day to day in each individual patient. Monitoring of antipsychotic drug concentrations in plasma might be of value provided the patients are treated with only 1 antipsychotic drug. Some st...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198611010-00003

    authors： Dahl SG

    更新日期：1986-01-01 00:00:00

  • Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.

    abstract：BACKGROUND AND OBJECTIVE:Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose-SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-016-0444-x

    authors： Kim E,Howes OD,Kim BH,Chon MW,Seo S,Turkheimer FE,Lee JS,Lee YS,Kwon JS

    更新日期：2017-04-01 00:00:00

  • Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

    abstract：:Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200847080-00001

    authors： Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

    更新日期：2008-01-01 00:00:00

  • Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen".

    abstract：: ...

    journal_title：Clinical pharmacokinetics

    pub_type： 评论,信件

    doi：10.1007/s40262-018-0665-2

    authors： van Rongen A,Välitalo PAJ,Knibbe CAJ

    更新日期：2018-07-01 00:00:00

  • Etodolac clinical pharmacokinetics.

    abstract：:Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. I...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199426040-00003

    authors： Brocks DR,Jamali F

    更新日期：1994-04-01 00:00:00

  • Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis.

    abstract：BACKGROUND:Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. OBJECTIVE:The purpose of our study was to investigate the pharmacokinetics (PK) of pemet...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00972-1

    authors： de Rouw N,Boosman RJ,Huitema ADR,Hilbrands LB,Svensson EM,Derijks HJ,van den Heuvel MM,Burger DM,Ter Heine R

    更新日期：2021-01-09 00:00:00

  • Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.

    abstract：BACKGROUND:Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS:This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subj...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-019-00743-7

    authors： Jauslin P,Kulkarni P,Li H,Vatakuti S,Hussain A,Wenning L,Kerbusch T

    更新日期：2019-08-01 00:00:00

  • Drug interactions with cisapride: clinical implications.

    abstract：:Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200039010-00004

    authors： Michalets EL,Williams CR

    更新日期：2000-07-01 00:00:00

  • Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

    abstract：:In the last 15 years the role of opioids in anaesthesia management has undergone dramatic change. Initially used as premedicants, or adjuvants to inhalation anaesthetic agents or as analgesics for postoperative pain relief, narcotics have now evolved into primary anaesthetic agents, primarily because of their ability ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198611010-00002

    authors： Davis PJ,Cook DR

    更新日期：1986-01-01 00:00:00